BioStem Technologies, Inc.
NASDAQ:BSEMBiotechnology
-$0.21 today
- Market cap
- $52.14M
- Beta
- 0.26
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.63
Volume 0.09M
Average 0.07M
BSEM Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
BioStem Technologies, Inc.NASDAQ: BSEM
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue growth accelerates
Q2 FY2026 cost of revenue of $3.06M rose 346.4% year over year, ahead of the -17.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 4.9% from the prior quarter. Over 3 fiscal years it compounded at +54.7% a year.
Context
- Cost of revenue amounted to 6.9% of revenue in FY2025, up 2.3 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +346.4% holds above the trailing-twelve-month pace of -17.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 3.26M USD
- Year-over-year change
- -76.3%
- 4-year CAGR
- +22.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.26M | -76.3% |
| FY2024 | 2024-12-31 | 13.75M | +989.4% |
| FY2023 | 2023-12-31 | 1.26M | +43.1% |
| FY2022 | 2022-12-31 | 881.75K | -40.2% |
| FY2021 | 2021-12-31 | 1.47M | — |
Cost of Revenue vs competitors
How BSEM compares with its peers on the latest reported figures
No competitor Cost of Revenue figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.34M | 6.88M | 16.69M | 301.83M | 47.48M |
| Cost of Revenue | 1.47M | 881.75K | 1.26M | 13.75M | 3.26M |
| Gross Profit | 2.87M | 5.99M | 15.42M | 287.86M | 44.22M |
| Gross Margin | 66.0% | 87.2% | 92.4% | 95.4% | 93.1% |
| Research & Development | 119.65K | 123.31K | 342K | 1.91M | 7.09M |
| Selling, General & Admin | 4.19M | 10.21M | 22.63M | 254.75M | 37.82M |
| Operating Expenses | 4.47M | 10.67M | 23.2M | 256.66M | 44.91M |
| Depreciation & Amortization | 283.9K | 243.42K | 229.02K | 293.22K | 219.42K |
| EBITDA | (602K) | (6.52M) | (7.55M) | 31.49M | (469.73K) |
| EBITDA Margin | -13.9% | -94.8% | -45.3% | 10.4% | -1.0% |
| Operating Income | (1.61M) | (4.68M) | (7.78M) | 31.2M | (689.15K) |
| Operating Margin | -37.0% | -68.1% | -46.6% | 10.3% | -1.5% |
| Interest Income | 0 | 0 | 0 | 0 | 413.85K |
| Interest Expense | 525.88K | 468.15K | 700.33K | 587.22K | 0 |
| Other Income / Expenses | 193.93K | (2.55M) | (704.02K) | (587.22K) | 299.5K |
| Income Before Tax | (1.41M) | (7.11M) | (8.48M) | 30.61M | (389.65K) |
| Pre-Tax Margin | -32.5% | -103.5% | -50.8% | 10.1% | -0.8% |
| Income Tax Expense | 0 | 0 | 0 | (1.27M) | 6.19M |
| Net Income | (1.45M) | (7.07M) | (8.48M) | 31.88M | (6.58M) |
| Net Margin | -33.3% | -102.9% | -50.8% | 10.6% | -13.9% |
| EPS (Basic) | (0.12) | (0.62) | (0.62) | 1.95 | (0.39) |
| EPS (Diluted) | (0.12) | (0.62) | (0.62) | 1.47 | (0.39) |
| Weighted Avg Shares | 11.69M | 11.41M | 13.71M | 16.37M | 16.73M |
| Weighted Avg Shares (Diluted) | 11.69M | 11.41M | 13.71M | 21.7M | 16.73M |
BioStem Technologies, Inc.
NASDAQ:BSEM
Intrinsic Alpha fair value
Locked
Current Price
$3.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.